个人科研网厅 | | 帮助
首都医科大学宣武医院知识库
高级检索
当前位置： 首页 > 详情页

Incidence, mortality, and disability-adjusted life years of female breast cancer in China, 2022

| 认领 | 导出 | |

文献详情

资源类型：
WOS体系：
Pubmed体系：

收录情况： ◇ SCIE ◇ 统计源期刊 ◇ CSCD-C ◇ 卓越：领军期刊 ◇ 中华系列

作者：
Sun Kexin[1] * ; Zhang Bailin[2] ; Lei Shaoyuan[3] ; Zheng Rongshou[1] ; Liang Xin[4] ; Li Li[1] ; Feng Xiaolong[5] ; Zhang Siwei[1] ; Zeng Hongmei[1] ; Yao Yifei[1] ; Ma Peiqing[5] ; Wang Shaoming[1] ; Chen Ru[1] ; Han Bingfeng[1] ; Wei Wenqiang[1] ; He Jie[6] ;
机构： [1]Office of Cancer Registry, National Cancer Center/National Clinical Research Center for Cancer/Cancer Hospital, Chinese Academy of Medical Sciences and Peking Union Medical College, Beijing 100021, China. [2]Department of Breast Surgical Oncology, National Cancer Center/National Clinical Research Center for Cancer/Cancer Hospital, Chinese Academy of Medical Sciences and Peking Union Medical College, Beijing 100021, China. [3]Department of Evidence-Based Medicine, Xuanwu Hospital, Capital Medical University, Beijing 100053, China. [4]Medical Statistics Office, National Cancer Center/National Clinical Research Center for Cancer/Cancer Hospital, Chinese Academy of Medical Sciences and Peking Union Medical College, Beijing 100021, China. [5]Department of Pathology, National Cancer Center/National Clinical Research Center for Cancer/Cancer Hospital, Chinese Academy of Medical Sciences and Peking Union Medical College, Beijing 100021, China. [6]Department of Thoracic Surgery, National Cancer Center/National Clinical Research Center for Cancer/Cancer Hospital, Chinese Academy of Medical Sciences and Peking Union Medical College, Beijing 100021, China.
出处：
DOI： 10.1097/CM9.0000000000003278
ISSN：

关键词： Female Breast cancer Incidence Mortality DALYs China Early detection of cancer Disease burden Invasive breast carcinoma Quality of life

摘要：
Breast cancer is ranked among the most prevalent malignancies in the Chinese female population. However, comprehensive reports detailing the latest epidemiological data and attributable disease burden have not been extensively documented.In 2018, high-quality cancer surveillance data were recorded in 700 population-based cancer registries in China. We extracted data on female breast cancers (International Classification of Diseases, Tenth Revision [ICD-10]: C50) and estimated the incidence and mortality in 2022 according to the baseline data and corresponding trends from 2010 to 2018. Pathological types were classified according to the ICD for Oncology, 3rd Edition codes. Disability-adjusted life years (DALYs) were calculated as the sum of the years of life lost (YLLs) and years lived with disability (YLDs).In 2022, approximately 357,200 new female breast cancer cases and 75,000 deaths occurred in China, accounting for 15.59% and 7.94% of total new cancer cases and deaths, respectively. The age-standardized incidence rate (ASIR) was 33.04 per 100,000. When analyzed by pathological type, the ASIRs for papillary neoplasms, invasive breast carcinoma, rare and salivary gland-type tumors, and other types were 1.13, 29.79, 0.24, and 1.88 per 100,000, respectively. The age-standardized mortality rate (ASMR) was 6.10 per 100,000. A total of 2,628,000 DALYs were found to be attributable to female breast cancer in China, comprising 2,278,300 YLLs and 349,700 YLDs. The ASIR, ASMR, and age-standardized rate (ASR) for DALYs in urban areas were consistently higher than those in rural areas. We observed a four-fold increase in the ASIR and ASR for DALYs and an eight-fold increase in the ASMR among females over 55 years compared with those aged under 55 years.These data provide invaluable insights into the latest epidemiology of female breast cancer in China and highlight the urgency for disease prevention and control strategy formulation.Copyright © 2024 The Chinese Medical Association, produced by Wolters Kluwer, Inc. under the CC-BY-NC-ND license.

基金：
the CAMS Innovation Fund for Medical Sciences (No. 2021-I2M-1-011).
语种：
外文
WOS：
PubmedID：
中科院(CAS)分区：
出版当年[2023]版：
大类 | 3 区 医学
小类 | 3 区 医学：内科
最新[2023]版：
大类 | 3 区 医学
小类 | 3 区 医学：内科
JCR分区：
出版当年[2022]版：
Q1 MEDICINE, GENERAL & INTERNAL
最新[2023]版：
Q1 MEDICINE, GENERAL & INTERNAL

影响因子： 最新[2023版] 最新五年平均 出版当年[2022版] 出版当年五年平均 出版前一年[2021版] 出版后一年[2023版]

第一作者：
第一作者机构： [1]Office of Cancer Registry, National Cancer Center/National Clinical Research Center for Cancer/Cancer Hospital, Chinese Academy of Medical Sciences and Peking Union Medical College, Beijing 100021, China.
通讯作者：
推荐引用方式(GB/T 7714)：
Sun Kexin,Zhang Bailin,Lei Shaoyuan,et al.Incidence, mortality, and disability-adjusted life years of female breast cancer in China, 2022[J].Chinese Medical Journal.2024,137(20):2429-2436.doi:10.1097/CM9.0000000000003278.
APA：
Sun Kexin,Zhang Bailin,Lei Shaoyuan,Zheng Rongshou,Liang Xin...&He Jie.(2024).Incidence, mortality, and disability-adjusted life years of female breast cancer in China, 2022.Chinese Medical Journal,137,(20)
MLA：
Sun Kexin,et al."Incidence, mortality, and disability-adjusted life years of female breast cancer in China, 2022".Chinese Medical Journal 137..20(2024):2429-2436

相关文献

[1]Burden of epilepsy in China and its provinces, 1990 to 2019: findings from the Global Burden of Disease Study 2019 [2]Taxotere-induced elevated expression of IL8 in carcinoma-associated fibroblasts of breast invasive ductal cancer [3]Combined diagnosis of breast cancer in the early stage by MRI and detection of gene expression [4]乳腺癌保留乳房手术与乳房全切患者生活质量对比研究 [5]Development of ipsilateral chest wall spindle cell carcinoma in a patient with invasive ductal breast carcinoma during postoperative adjuvant therapy: A case report [6]Association between Body Mass Index and All-Cause Mortality in Hypertensive Adults: Results from the China Stroke Primary Prevention Trial (CSPPT) [7]卒中的疾病负担 [8]我院乳腺外科开展人文护理的实践与成效 [9]Temporal trend and attributable risk factors of Alzheimer's disease and other dementias burden in China: Findings from the Global Burden of Disease Study 2021 [10]俱乐部活动对乳腺癌术后患者生活质量的影响

资源点击量：16408 今日访问量：0 总访问量：869 更新日期：2025-01-01 建议使用谷歌、火狐浏览器 常见问题

版权所有©2020 首都医科大学宣武医院 技术支持：重庆聚合科技有限公司 地址：北京市西城区长椿街45号宣武医院